Research Reference
Exenatide
First-in-class GLP-1 receptor agonist derived from Gila monster venom
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Exenatide (Byetta, Bydureon) was the first GLP-1 receptor agonist approved for type 2 diabetes, originally derived from a protein found in Gila monster venom. It enhances glucose-dependent insulin secretion.
Dosing Reference
Reconstitution
Add 1 mL bacteriostatic water to the 0.25 mg vial. Resulting concentration: 0.25 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 5 mcg | 2 units | 0.02 mL | SubQ, twice dailyByetta starting dose (FDA) |
| 10 mcg | 4 units | 0.04 mL | SubQ, twice dailyByetta max dose (FDA) |
| 2 mg | 800 units | 8 mL | SubQ, once weeklyBydureon dose (FDA) |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Exenatide is supplied in two FDA-approved forms: Byetta (5 or 10 mcg pre-filled pens, twice-daily) and Bydureon BCise (2 mg once-weekly pre-filled pen or vial with microspheres). Neither is user-reconstituted from lyophilized powder. Compounded research-peptide forms are not FDA-approved.
For compounded forms, concentration depends on vial size and diluent volume; no standard compounded protocol exists. Compounded forms are not FDA-approved.
Cycling Protocol
Byetta: start 5 mcg twice daily before meals, increase to 10 mcg twice daily after one month as tolerated. Bydureon: 2 mg once weekly, any time of day. Used as chronic therapy with no fixed cycle end.
Routes of Administration
Subcutaneous injection (only established route): Byetta twice daily before morning/evening meals; Bydureon once weekly into abdomen, thigh, or upper arm.
No oral, intranasal, or intravenous route is established. Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | GLP-1 + Lifestyle | Exenatide + diet/exercise | Standard FDA-approved T2D protocol | | Combination Therapy | Exenatide + metformin / sulfonylurea | Studied T2D combinations (under medical supervision) |
Combining multiple GLP-1 agonists is not recommended. Compounded forms are not FDA-approved.
Side Effects & Safety
- Nausea — most common, usually transient
- Vomiting, diarrhea, constipation — common GI effects
- Hypoglycemia — risk, especially with sulfonylureas/insulin
- Pancreatitis — rare; discontinue if suspected
- Injection-site nodules — more common with Bydureon microspheres
- Black-box warning: thyroid C-cell tumors in rodents; contraindicated in personal/family history of MTC or MEN2
Exenatide (Byetta/Bydureon) is FDA-approved. Compounded research-peptide forms are not FDA-approved.
Research Basis
Exenatide is a GLP-1 receptor agonist derived from the saliva of the Gila monster (exendin-4), with ~53% homology to human GLP-1 and a longer half-life.
Mechanism: GLP-1 receptor agonism — glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, appetite reduction.
Clinical evidence: FDA-approved for type 2 diabetes (Byetta 2005, Bydureon 2012/2017). Demonstrated glycemic improvement and modest weight loss.
FDA-approved for T2D. Compounded research-peptide forms are not FDA-approved.